Leerink Partnrs Estimates Beta Bionics FY2024 Earnings

Beta Bionics, Inc. (NASDAQ:BBNX) – Equities research analysts at Leerink Partnrs issued their FY2024 earnings per share estimates for Beta Bionics in a report issued on Monday, February 24th. Leerink Partnrs analyst M. Kratky expects that the company will post earnings per share of ($1.66) for the year. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. Leerink Partnrs also issued estimates for Beta Bionics’ Q4 2024 earnings at ($0.42) EPS, Q1 2025 earnings at ($0.50) EPS, Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.82) EPS, FY2026 earnings at ($1.94) EPS, FY2027 earnings at ($2.28) EPS, FY2028 earnings at ($1.42) EPS and FY2029 earnings at ($0.95) EPS.

BBNX has been the topic of a number of other reports. LADENBURG THALM/SH SH started coverage on shares of Beta Bionics in a research note on Thursday, February 20th. They issued a “neutral” rating and a $20.00 target price on the stock. Baird R W raised Beta Bionics to a “hold” rating in a research note on Thursday, February 20th. Piper Sandler started coverage on Beta Bionics in a research report on Monday. They set an “overweight” rating and a $26.00 target price for the company. Robert W. Baird began coverage on Beta Bionics in a research report on Thursday, February 20th. They set a “neutral” rating and a $20.00 price target on the stock. Finally, Lake Street Capital initiated coverage on Beta Bionics in a report on Monday. They issued a “buy” rating and a $30.00 price objective for the company. Three analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Beta Bionics has an average rating of “Moderate Buy” and an average target price of $24.83.

Beta Bionics Trading Down 6.9 %

BBNX stock opened at $19.17 on Wednesday. Beta Bionics has a 12 month low of $19.08 and a 12 month high of $24.50.

Insider Buying and Selling

In other news, major shareholder Hadley Harbor Aggre Wellington bought 1,000,000 shares of the stock in a transaction on Friday, January 31st. The stock was bought at an average cost of $17.00 per share, for a total transaction of $17,000,000.00. Following the completion of the purchase, the insider now directly owns 3,901,599 shares in the company, valued at approximately $66,327,183. The trade was a 34.46 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mike Mensinger purchased 33,350 shares of Beta Bionics stock in a transaction dated Friday, January 31st. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $566,950.00. Following the completion of the transaction, the insider now owns 59,019 shares of the company’s stock, valued at approximately $1,003,323. This represents a 129.92 % increase in their position. The disclosure for this purchase can be found here.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.